🌍·12h agodiscovery
Teva’s TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trial
Publisher
T
The Clinical Trial Vanguard
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Clinical Trial Vanguard
- Region
- Global
- Scope
- discovery
- Published
- September 19, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Clinical Trial Vanguard
Scope: discovery
Related coverage
More related coverage
AD HOC NEWS/3h ago
West Pharmaceutical stock holds Moderate Buy rating as Annex 1 work shapes outlook
washingtonpost.com/4h ago
Secret contracts reveal undisclosed terms in Trump’s drug-pricing deals
AD HOC NEWS/4h ago
Oncolytics Biotech stock lacks a fresh catalyst and stays near $0.77
Yahoo Finance/5h ago